Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979408599> ?p ?o ?g. }
- W2979408599 endingPage "1677" @default.
- W2979408599 startingPage "1677" @default.
- W2979408599 abstract "Abstract Introduction: MCL is a mature B-cell neoplasm characterized by t(11;14) (q13;q32) and cyclin D1 (CCND1) overexpression. Molecular studies have revealed other alterations in cell-cycle regulation, DNA damage response and cell survival pathways, with a landscape of somatic mutations being recently identified. CNS involvement is a well known complication, occurring in 4-26% of MCL at five years, with an ominous significance. Although different clinical variables have been identified as risk factors for CNS infiltration, the biological parameters related to this complication have not been extensively studied. The aim of the study was to explore the biological parameters associated with CNS involvement in a multicentre and retrospective series of MCL patients. Patients and Methods: 285 patients (M:74%; 64 yr) diagnosed of MCL between 1990-2014 (median survival of 4 years) were analysed. In addition to standard clinico-biological variables, IGHV mutational analysis, chromosomal alteration studies and Sanger sequencing of NOTCH1, NOTCH2, TP53, BIRC3, WHSC1, MEF2B, MLL2, TLR2 and PRDM1 were performed. Results: CNS involvement was observed in 15/285 MCL patients (5.2%), with a 5-yr risk of 9.1% (95%CI: 4.6-13.6), one patient at diagnosis, and at first or second/ulterior progressions in 7 cases each. The clinical, pathological and molecular risk factors identified are detailed in the Table. In addition to what has been already described, CNS involvement was usually observed in MCL cases with a clinical nodal presentation (p=0.05). In fact, no indolent MCL with a non-nodal presentation developed this complication during the follow-up period. No differences were observed in the risk of CNS involvement between patients treated in first-line with conventional or high-dose intense treatment (5-yr risk: 6.1%+/-6% vs. 10.7%+/-10.6%, p=ns). Regarding the biological features, no differences in terms of the IGHV mutational status were observed in cases developing CNS involvement compared to the others (75% vs. 68.7%, using 97% identity cut-off). Similarly, the IGHV gene usage of CNS involved cases corresponded to the more frequent IGHV genes observed in MCL (usually IGHV1-18, IGHV3-23, IGHV4-34, IGHV4-59). Although not significant, a predominance of high number copy number alterations (CNA) (>4) could be observed in the genetic study of MCL cases with CNS involvement as could be expected for the enrichment in blastoid variants (up to 50% of these cases). In fact, we did not observe any case with CNS involvement among those cases with 3 or less CNA. CNS involvement was not related to common poor prognosis genetic alterations such as 9p, 11p and 17p losses, but the presence of 8q gains was associated with a higher risk of CNS involvement (p=0.05). We did not find any significant association between CNS involvement and the large number of oncogenic mutations studied. Conclusions: CNS involvement in MCL is associated with initial aggressive clinico-biological characteristics. Non-nodal MCL cases with a low number of genetic alterations did not present CNS involvement. Finally, the presence of 8q gains was associated with a higher risk of CNS infiltration. Table Initial Clinical Features Category N 5 yr-CNS involvement (%, 95%CI) HR p Performance status (ECOG) > 1 8/51 41.5 (+/-28) 4.2 .003 ≤ 1 7/128 9.4 (+/-5.5) Nodal disease Yes 14/185 13.3 (+/-7.6) 6.1 .05 No 1/77 1.4 (+/-2.7) Hemoglobin (g/L) < 105 12/93 24.7 (+/-14.7) 3.2 .05 ≥ 105 3/78 5.3 (+/-6.3) LDH > ULN 4/89 27.1(+/-19.4) 6.7 <.001 < ULN 11/137 5.6 (+/-6.3) B2microglobulin > ULN 11/114 21.6 (+/-14.9) 3.5 .04 < ULN 3/66 8.7(+/-10) Molecular & Pathological data Histological variant Blastoid 6/58 17.3 (+/-13.7) 3.5 .02 Others 8/156 1.3 (+/-7.2) Ki-67 > 30% 5/44 17.5 (+/-14.9) 3.6 .06 ≤ 30% 3/61 6.7 (+/-9.4) SOX11 Positive 8/153 2.9 (+/- 5.7) 2.6 ns Negative 1/42 2.1 (+/-2.4) IGHV ≥97% 6/109 9.5 (+/-9.6) 1.9 ns <97% 2/49 6 (+/-8.2) CNA > 4 2/87 3.9 (+/-5.7) 1.1 ns ≤ 4 1/44 2.3 (+/-4.3) Chromotripsis Yes 1/17 12.5 (+/-22) 3.2 ns No 2/106 1.9 (+/-2.7) 8q gain Yes 2/30 13.1(+/-19) 7.5 .05 No 2/97 1 (+/-1.96) CNA: copy number alteration; IGHV: immunoglobulin heavy chain; LDH: Lactate dehydrogenase Disclosures No relevant conflicts of interest to declare." @default.
- W2979408599 created "2019-10-18" @default.
- W2979408599 creator A5002096122 @default.
- W2979408599 creator A5003201244 @default.
- W2979408599 creator A5005178530 @default.
- W2979408599 creator A5007551486 @default.
- W2979408599 creator A5010733763 @default.
- W2979408599 creator A5012101254 @default.
- W2979408599 creator A5020702876 @default.
- W2979408599 creator A5024516606 @default.
- W2979408599 creator A5028397596 @default.
- W2979408599 creator A5029161067 @default.
- W2979408599 creator A5029235110 @default.
- W2979408599 creator A5030524385 @default.
- W2979408599 creator A5030831053 @default.
- W2979408599 creator A5032015264 @default.
- W2979408599 creator A5035896968 @default.
- W2979408599 creator A5049385918 @default.
- W2979408599 creator A5051606383 @default.
- W2979408599 creator A5052695708 @default.
- W2979408599 creator A5058191832 @default.
- W2979408599 creator A5061167008 @default.
- W2979408599 creator A5063421244 @default.
- W2979408599 creator A5064518399 @default.
- W2979408599 creator A5066377227 @default.
- W2979408599 creator A5070169057 @default.
- W2979408599 creator A5074453036 @default.
- W2979408599 creator A5075157221 @default.
- W2979408599 creator A5076803852 @default.
- W2979408599 creator A5077013079 @default.
- W2979408599 creator A5078861956 @default.
- W2979408599 creator A5078999372 @default.
- W2979408599 creator A5081421128 @default.
- W2979408599 creator A5081956058 @default.
- W2979408599 creator A5085727142 @default.
- W2979408599 creator A5085736332 @default.
- W2979408599 date "2014-12-06" @default.
- W2979408599 modified "2023-10-16" @default.
- W2979408599 title "Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases" @default.
- W2979408599 doi "https://doi.org/10.1182/blood.v124.21.1677.1677" @default.
- W2979408599 hasPublicationYear "2014" @default.
- W2979408599 type Work @default.
- W2979408599 sameAs 2979408599 @default.
- W2979408599 citedByCount "0" @default.
- W2979408599 crossrefType "journal-article" @default.
- W2979408599 hasAuthorship W2979408599A5002096122 @default.
- W2979408599 hasAuthorship W2979408599A5003201244 @default.
- W2979408599 hasAuthorship W2979408599A5005178530 @default.
- W2979408599 hasAuthorship W2979408599A5007551486 @default.
- W2979408599 hasAuthorship W2979408599A5010733763 @default.
- W2979408599 hasAuthorship W2979408599A5012101254 @default.
- W2979408599 hasAuthorship W2979408599A5020702876 @default.
- W2979408599 hasAuthorship W2979408599A5024516606 @default.
- W2979408599 hasAuthorship W2979408599A5028397596 @default.
- W2979408599 hasAuthorship W2979408599A5029161067 @default.
- W2979408599 hasAuthorship W2979408599A5029235110 @default.
- W2979408599 hasAuthorship W2979408599A5030524385 @default.
- W2979408599 hasAuthorship W2979408599A5030831053 @default.
- W2979408599 hasAuthorship W2979408599A5032015264 @default.
- W2979408599 hasAuthorship W2979408599A5035896968 @default.
- W2979408599 hasAuthorship W2979408599A5049385918 @default.
- W2979408599 hasAuthorship W2979408599A5051606383 @default.
- W2979408599 hasAuthorship W2979408599A5052695708 @default.
- W2979408599 hasAuthorship W2979408599A5058191832 @default.
- W2979408599 hasAuthorship W2979408599A5061167008 @default.
- W2979408599 hasAuthorship W2979408599A5063421244 @default.
- W2979408599 hasAuthorship W2979408599A5064518399 @default.
- W2979408599 hasAuthorship W2979408599A5066377227 @default.
- W2979408599 hasAuthorship W2979408599A5070169057 @default.
- W2979408599 hasAuthorship W2979408599A5074453036 @default.
- W2979408599 hasAuthorship W2979408599A5075157221 @default.
- W2979408599 hasAuthorship W2979408599A5076803852 @default.
- W2979408599 hasAuthorship W2979408599A5077013079 @default.
- W2979408599 hasAuthorship W2979408599A5078861956 @default.
- W2979408599 hasAuthorship W2979408599A5078999372 @default.
- W2979408599 hasAuthorship W2979408599A5081421128 @default.
- W2979408599 hasAuthorship W2979408599A5081956058 @default.
- W2979408599 hasAuthorship W2979408599A5085727142 @default.
- W2979408599 hasAuthorship W2979408599A5085736332 @default.
- W2979408599 hasConcept C121608353 @default.
- W2979408599 hasConcept C126322002 @default.
- W2979408599 hasConcept C142724271 @default.
- W2979408599 hasConcept C143998085 @default.
- W2979408599 hasConcept C199835354 @default.
- W2979408599 hasConcept C2777525834 @default.
- W2979408599 hasConcept C2777609679 @default.
- W2979408599 hasConcept C2777938653 @default.
- W2979408599 hasConcept C2778461978 @default.
- W2979408599 hasConcept C2779338263 @default.
- W2979408599 hasConcept C29537977 @default.
- W2979408599 hasConcept C71924100 @default.
- W2979408599 hasConcept C86803240 @default.
- W2979408599 hasConceptScore W2979408599C121608353 @default.
- W2979408599 hasConceptScore W2979408599C126322002 @default.
- W2979408599 hasConceptScore W2979408599C142724271 @default.
- W2979408599 hasConceptScore W2979408599C143998085 @default.
- W2979408599 hasConceptScore W2979408599C199835354 @default.
- W2979408599 hasConceptScore W2979408599C2777525834 @default.